Digital therapeutics for adolescent mental health

limbix spark

Investigational digital therapeutic for adolescent depression

Adolescent depression and suicide are on the rise, yet effective care is limited by long waitlists and large out-of-pocket costs for therapy, limited pharmacological options, and stigma surrounding mental health.

If Limbix Spark is FDA cleared it will be the first prescription digital therapeutic designed to support adolescents with depression. Spark is a multi-week cognitive behavioral therapy based program focused on the completion of value-based activities that spark feelings of pleasure or mastery.


Prescribed by doctors

Limbix is actively creating prescription digital therapeutics (PDTs) to enable doctors to prescribe digital, evidence-based, therapeutic interventions for adolescent mental health.

PDTs require strict compliance with FDA quality management standards and are validated through rigorous clinical trials. Upon FDA clearance, PDTs can be prescribed by a doctor to treat specific medical conditions.
User research sessions

Designed for teens

Limbix creates digital therapeutics with significant input from teenagers who provide us valuable feedback. If you are a teen interested in helping Limbix design thoughtful digital experiences for current and future generations of young people, sign up for our User Research Sessions!

Learn More
Co-developed with leading researchers and clinicians
Physician Advisory Group

Limbix relies on clinical experts who provide critical product feedback to help ensure the digital therapeutics we create are evidence-based and beneficial for patients. If you are a physician looking to connect with Limbix to provide your input, please join our Physician Advisory Group.

Join Physician Advisory Group